Results 181 to 190 of about 15,755 (201)

Daratumumab

Reactions Weekly, 2023
openaire   +2 more sources

Daratumumab

Reactions Weekly, 2017
openaire   +2 more sources

Daratumumab

Reactions Weekly, 2018
  +4 more sources

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Lancet, The, 2020
Athanasios Dimopoulos, Hang Quach, María-Victoria Mateos   +2 more
exaly  

Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond

Nature Reviews Clinical Oncology, 2021
Ghulam Rehman Mohyuddin, Hira S Mian
exaly  

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Lancet, The, 2020
María-Victoria Mateos, Michele Cavo, Joan Bladé   +2 more
exaly  

Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus

New England Journal of Medicine, 2020
Lennard Ostendorf, Marie E Burns, Pawel Durek   +2 more
exaly  

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Lancet, The, 2016
Sagar Lonial, Saad Z Usmani, Ajai Chari
exaly  

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Lancet, The, 2019
Phillipe Moreau, Michel M Attal, Bertrand Arnulf   +2 more
exaly  

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

New England Journal of Medicine, 2015
Torben Plesner, Jacob P Laubach, Hareth Nahi   +2 more
exaly